rts logo

Are we looking at the next big move in Aurinia Pharmaceuticals Inc (AUPH)?

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is -44.27% lower on its value in year-to-date trading and has touched a low of $4.85 and a high of $12.43 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AUPH stock was last observed hovering at around $5.00 in the last trading session, with the day’s gains setting it 0.01%.

Currently trading at $5.01, the stock is -5.16% and -22.86% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.37 million and changing 0.20% at the moment leaves the stock -40.26% off its SMA200. AUPH registered -54.41% loss for a year compared to 6-month loss of -37.22%. The firm has a 50-day simple moving average (SMA 50) of $2.69 and a 200-day simple moving average (SMA200) of -$7.48.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The stock witnessed a -14.21% gain in the last 1 month and extending the period to 3 months gives it a -46.07%, and is 0.00% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.34% over the week and 3.59% over the month.

Aurinia Pharmaceuticals Inc (AUPH) has around 300 employees, a market worth around $724.55M and $175.51M in sales. Fwd P/E is 12.07. Profit margin for the company is -44.45%. Distance from 52-week low is 3.30% and -59.69% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.96%).

Aurinia Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.14 with sales reaching $47.45M over the same period.The EPS is expected to grow by 90.12% this year, but quarterly earnings will post 27.80% year-over-year. Quarterly sales are estimated to grow 37.90% in year-over-year returns.

Aurinia Pharmaceuticals Inc (AUPH) Top Institutional Holders

260 institutions hold shares in Aurinia Pharmaceuticals Inc (AUPH), with institutional investors hold 41.71% of the company’s shares. The shares outstanding are 143.83M, and float is at 127.86M with Short Float at 8.33%. Institutions hold 38.61% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 8.33 million shares valued at $80.66 million. The investor’s holdings represent 5.81% of the AUPH Shares outstanding. As of Jun 29, 2023, the second largest holder is Armistice Capital, LLC with 4.69 million shares valued at $45.42 million to account for 3.27% of the shares outstanding. The other top investors are NEA Management Company, LLC which holds 3.97 million shares representing 2.77% and valued at over $38.43 million, while State Street Corporation holds 1.84% of the shares totaling 2.63 million with a market value of $25.48 million.

Aurinia Pharmaceuticals Inc (AUPH) Insider Activity

The most recent transaction is an insider sale by Greenleaf Peter,the company’sChief Executive Officer. SEC filings show that Greenleaf Peter sold 126,981 shares of the company’s common stock on Mar 06 ’24 at a price of $5.60 per share for a total of $0.71 million. Following the sale, the insider now owns 1.52 million shares.

Aurinia Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 06 ’24 that Robertson Stephen P. (EVP, General Counsel) sold a total of 57,745 shares of the company’s common stock. The trade occurred on Mar 06 ’24 and was made at $5.60 per share for $0.32 million. Following the transaction, the insider now directly holds 0.44 million shares of the AUPH stock.

Still, SEC filings show that on Mar 06 ’24, Donley Matthew Maxwell (EVP, Ops & Strategy) disposed off 40,665 shares at an average price of $5.51 for $0.22 million. The insider now directly holds 584,072 shares of Aurinia Pharmaceuticals Inc (AUPH).

Related Posts